Rheumatoid arthritis

Don’t exceed recommended dose with tofacitinib in RA, FDA advises

The US Federal Drug Administration (FDA) has issued a safety advisory statement for tofacitinib (Xeljanz) warning prescribers not to exceed the recommended dose in patients with rheumatoid arthritis. The alert follows a postmarketing safety clinical trial of tofactinib in combination with methotrexate that found an increased risk of pulmonary embolism and death with a 10mg ...

Already a member?

Login to keep reading.

© 2021 the limbic